Don't miss your email and connect your friends with TalkKing!
Since the breakthrough of COVID-19 vaccines, mRNA therapeutics have rapidly advanced into cancer immunotherapy. Although most mRNA cancer vaccines remain in early clinical stages, they are showing strong potential by targeting tumor-associated antigens (TAAs) such as MAGE-A1, gp100, and PSA. When combined with immune checkpoint inhibitors (e.g., PD-1 blockers), their efficacy improves significantly. Recent melanoma trials involving combination therapies with PD-1 inhibitors have reported relapse-free survival rates of approximately 75%—a notable advancement in treatment outcomes.
At
Synbio Technologies
, we empower mRNA-based cancer research with:
●
High-yield
in vitro
transcription
for large-scale mRNA production.
●
Codon optimization
to improve translation and immune response.
●
RNA modifications
(5′ cap, poly(A) tail) for stability and potency.
●
Full-service workflows
from DNA templates to IVT synthesis.
●
Tailored, scalable solutions
to accelerate clinical development.
Fuel innovation. Expand opportunity. Grow with Synbio
Tech
!
Inquire Now
Thank you for connecting with us! Click "
Subscribe
" to receive valuable insights and news. If you prefer not to receive further emails, just hit "
Unsubscribe
" — your choice is always respected.
Synbio Technologies LLC
9 Deer Prk Dr., Suite J-25, Monmouth Junction, NJ 08852, USA